MannKind (NASDAQ:MNKD) First Quarter 2025 Results

Key Financial Results

Revenue: US$78.4m (up 18% from 1Q 2024). Net income: US$13.2m (up 24% from 1Q 2024). Profit margin: 17% (in line with 1Q 2024). EPS: US$0.043 (up from US$0.039 in 1Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqGM:MNKD Earnings and Revenue Growth May 10th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

MannKind Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 3.3%. Earnings per share (EPS) missed analyst estimates by 5.9%.

Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 8.8% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk.  We've identified 3 warning signs  with MannKind (at least 2 which are potentially serious), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments